NCT02127801View on ClinicalTrials.gov

Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Allergy
Interventions
DRUG

REGN1908-1909

DRUG

placebo

Trial Locations (5)

Unknown

Groningen

Auckland

Christchurch

Lund

London

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY

NCT02127801 - Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants | Biotech Hunter | Biotech Hunter